miR3652, H4C1 and HDAC1 epigenetic regulators were selected from those 200 genes that showed the greatest difference in expression levels in the case of comparing nilotinib- and idasanutlin-treated and untreated CML cells. This evidence concerns the gene HDAC1 and chronic myelogenous leukemia, BCR-ABL1 positive.